Mechanism or Memorisation? Stress-Testing Relational Generalisation in Drug–Target Interaction Prediction
Favour Igwezeke ⋅ Mary Adewunmi
Abstract
Drug–target interaction (DTI) models are often evaluated on held-out interactions for which the drug and target have each appeared elsewhere during training. Such warm-start evaluation establishes that the exact edge is unseen, but it does not establish whether the relationship is supported by analogous training interactions. We introduce relational support, a training-relative evaluation approach that distinguishes familiarity with the individual drug and target from familiarity with their relationship. Using 1,584,215 positive interactions derived from BindingDB, we construct a positive-edge holdout containing 80,094 warm/warm interactions with valid molecular and protein similarity representations. We quantify marginal drug and target familiarity, same-endpoint support, and cross-endpoint relational support using chirality-aware molecular fingerprints and full-length protein sequence identity. We then evaluate three DTI representation families—MoLFormer+ESM-2, ChemBERTa+ESM-2, and Morgan fingerprints+ESM-2—under an identical supervised prediction head that never receives relational-support quantities as input. Across all three representation families, matched average precision was higher for high- than low-relational-support positives: Core-4 $\mathrm{SRG}_X$ ranged from +0.0064 to +0.0099, with all model-level 95% bootstrap confidence intervals above zero. Higher $R_X$ was also associated with lower adjusted positive-pair loss ($\beta_X = -0.0863$ to $-0.1933$). High-confidence false negatives were rare (7–22 of 8,010 top-confidence positives per seed) but sharply localised, with mean $R_X$ 0.363–0.369 lower than for high-confidence correct predictions. Thus, near-ceiling warm-start ranking can coexist with a small, systematically structured error tail in relationally unsupported regions. In practical DTI screening, relationship-level support may help identify apparently familiar drug–target pairs that remain weakly supported by training data and may warrant additional validation before experimental prioritisation.
Chat is not available.
Successful Page Load